Online citations, reference lists, and bibliographies.
← Back to Search

A Phase I Study Of Extrapleural Pneumonectomy And Intracavitary Intraoperative Hyperthermic Cisplatin With Amifostine Cytoprotection For Malignant Pleural Mesothelioma.

L. Zellos, W. Richards, Leah Capalbo, M. Jaklitsch, L. Chirieac, B. Johnson, R. Bueno, D. Sugarbaker
Published 2009 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
OBJECTIVE This study was undertaken to determine maximum tolerated dose and toxicity of intraoperative intracavitary hyperthermic cisplatin perfusion with amifostine after extrapleural pneumonectomy for malignant pleural mesothelioma. METHODS Patients with mesothelioma were prospectively enrolled. Those with resectable disease received amifostine and 1-hour hyperthermic cisplatin perfusion of ipsilateral hemithorax and abdomen. Morbidity, recurrence, and survival were recorded. RESULTS Forty-two patients were enrolled; 29 underwent resection (operative mortality 7%, 2/29). Median age was 57 years. Eighteen were in pathologic stage I or II; 11 were in stage III. Median hospitalization was 15 days. Common complications were atrial fibrillation (66%, 19 patients), deep venous thrombosis (31%, 9 patients), and grade 3+ renal toxicity (31%, 9 patients). Feasibility was determined. Renal toxicity was unrelated to cisplatin dose, with no maximum tolerated dose determined. Overall median survival was 17 months (resected 20 months, unresected 10 months). Median survivals were 26 months for patients receiving higher cisplatin doses and 16 months for those receiving lower doses (P = .35). Survival was significantly longer with negative extrapleural nodes (31 vs 14 months, P = .0115) and early stage (all resected 35 months for stage I-II vs 14 months for stage III, P = .0022, epithelial 39 months for stage I-II vs 15 months for stage III, P = .0072). CONCLUSION Early stage and negative extrapleural lymph nodes were associated with prolonged survival. Single-dose amifostine did not protect adequately against cisplatin-induced renal toxicity. Additional cytoprotective strategies are needed to allow determination of cisplatin maximum tolerated dose.
This paper references
10.1634/THEONCOLOGIST.10-2-112
Update on chemotherapeutic agents utilized for perioperative intraperitoneal chemotherapy.
P. Sugarbaker (2005)
10.1067/MTC.2001.116560
A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
V. Rusch (2001)
10.1038/sj.bjc.6600118
Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma
J. van Haarst (2002)
Innovative therapies : intraoperative intracavitary che
MY Chang (2004)
10.1016/S0003-4975(01)02786-2
Resection and perfusion thermochemotherapy: a new approach for the treatment of thymic malignancies with pleural spread.
Y. Refaely (2001)
Activation of circulating platelets by hyperthermal stress.
H. Take (1996)
10.1016/J.JTCVS.2005.08.012
Intrapleural topical application of cisplatin with the surgical carrier Vivostat increases the local drug concentration in an immune-competent rat model with malignant pleuromesothelioma.
D. Lardinois (2006)
10.1200/JCO.2004.10.071
Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.
W. Weder (2004)
10.1200/JCO.2005.04.6813
Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma.
W. Richards (2006)
Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer:A Gynecologic Oncology Group study
P. Box (2006)
10.1200/JCO.1989.7.8.1157
Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients.
P. Ruffié (1989)
10.1016/S1547-4127(04)00109-4
Innovative therapies: intraoperative intracavitary chemotherapy.
M. Chang (2004)
10.1200/JCO.2005.07.167
Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01.
B. Movsas (2005)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.3109/02656739609023687
Effects of hyperthermal stress on the fibrinolytic system.
K. Tamura (1996)
10.1038/bjc.1995.546
Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: a randomised phase II study.
D. Betticher (1995)
10.1158/1078-0432.CCR-03-0486
Intraperitoneal Cisplatin with Intraperitoneal Gemcitabine in Patients with Epithelial Ovarian Cancer
P. Sabbatini (2004)
10.1200/JCO.1996.14.6.1913
Amifostine, cisplatin, and vinblastine in metastatic non-small-cell lung cancer: a report of high response rates and prolonged survival.
J. Schiller (1996)
10.1200/JCO.1994.12.6.1156
A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma.
V. Rusch (1994)
10.1200/JCO.1999.17.10.3333
American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants.
M. Hensley (1999)
10.1053/SONC.2002.30230
Multimodality treatment of diffuse malignant pleural mesothelioma.
L. Zellos (2002)
10.1023/A:1008353505916
Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer. EORTC Head and Neck Cooperative Group.
A. Planting (1999)
10.1200/JCO.1996.14.7.2101
Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer.
G. Kemp (1996)
10.1016/S0022-5223(99)70469-1
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
D. Sugarbaker (1999)
10.1080/026567399285738
The effects of intentional hyperthermia on the Thrombelastograph and the Sonoclot analyser.
E. Pivalizza (1999)



This paper is referenced by
10.1007/s00104-019-0989-y
Hypertherme intrathorakale Chemotherapie in der Thoraxchirurgie
H. Hofmann (2019)
10.21037/atm.2017.03.78
Intraoperative intracavitary hyperthermic chemotherapy for malignant pleural mesothelioma.
K. Okabe (2017)
10.1053/j.semtcvs.2009.07.003
Making the case for molecular staging of malignant pleural mesothelioma.
R. Bueno (2009)
10.1245/s10434-011-1728-x
Summary of Prognostic Factors and Patient Selection for Extrapleural Pneumonectomy in the Treatment of Malignant Pleural Mesothelioma
Mbbs Christopher Cao BSc (2011)
10.5114/kitp.2017.72232
Malignant mesothelioma as a difficult interdisciplinary problem
W. Rokicki (2017)
10.1007/s00104-010-1926-2
Zytoreduktive Chirurgie und hypertherme intrathorakale Chemotherapieperfusion
H. Hofmann (2010)
10.1007/s11864-011-0154-4
Surgical Treatment of Malignant Pleural Mesothelioma
A. Kaufman (2011)
10.1097/JTO.0b013e3181ed0489
A Systematic Review of Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma
C. Cao (2010)
10.1510/icvts.2009.223768
Cold-plasma coagulation in the treatment of malignant pleural mesothelioma: results of a combined approach.
M. Hoffmann (2010)
10.5772/53397
Recent Advances in Surgical Techniques for Multimodality Treatment of Malignant Pleural Mesothelioma
C. Asteriou (2013)
10.21037/tlcr.2017.05.04
Intraoperative adjuncts for malignant pleural mesothelioma.
W. Chan (2017)
10.1016/j.jtho.2018.04.032
A Phase I Trial of Surgical Resection and Intraoperative Hyperthermic Cisplatin and Gemcitabine for Pleural Mesothelioma
B. Burt (2018)
10.1016/j.lungcan.2013.11.026
A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma.
C. Cao (2014)
10.1177/2373997515595219
Extrapleural Pneumonectomy A Blessing or a Curse in the Management of Pleural Malignant Mesothelioma
S. Qadri (2015)
10.14797/mdcj-15-4-282
Electrophysiologic Complications in Cancer Patients.
Dae Hyun Lee (2019)
10.1117/12.2526248
Feasibility trial assessing intrapleural photodynamic therapy combined with pleurectomy/decortication then chemotherapy in malignant pleural mesothelioma patients
S. Mordon (2019)
10.1093/ejcts/ezs418
Cytoreductive surgery and hyperthermic intrathoracic chemotherapy perfusion for malignant pleural tumours: perioperative management and clinical experience.
M. Ried (2013)
10.1007/s11864-011-0146-4
The Evolution of Multimodality Therapy for Malignant Pleural Mesothelioma
M. Zauderer (2011)
10.1016/j.jtcvs.2010.09.032
Optimized intrapleural cisplatin chemotherapy with a fibrin carrier after extrapleural pneumonectomy: a preclinical study.
I. Opitz (2011)
10.1053/j.semtcvs.2009.07.004
Multimodality strategies in malignant pleural mesothelioma.
W. Weder (2009)
10.1053/j.semtcvs.2009.07.006
Mesothelioma: path to multimodality treatment.
S. Su (2009)
10.1007/s00398-012-0931-9
Behandlung maligner Tumoren der Pleura
M. Ried (2012)
10.1016/j.semradonc.2010.01.009
Pleural malignancies.
Joseph S. Friedberg (2010)
10.1016/j.jtcvs.2009.02.046
Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study.
T. R. Tilleman (2009)
10.1016/j.jtcvs.2014.01.007
WITHDRAWN: Is there life after the Mesothelioma and Radical Surgery trial? Does extrapleural pneumonectomy still have a role in the management of pleural mesothelioma? A 13-year, single-center experience.
S. Qadri (2014)
10.21037/jtd.2016.06.04
Clinical outcomes of cytoreductive surgery combined with intrapleural perfusion of hyperthermic chemotherapy in advanced lung adenocarcinoma with pleural dissemination.
Eunjue Yi (2016)
10.1586/ers.10.35
Surgery for malignant pleural mesothelioma
D. Sugarbaker (2010)
10.1016/j.amjsurg.2017.02.003
The seven attributes of the academic surgeon: Critical aspects of the archetype and contributions to the surgical community.
T. Rosengart (2017)
10.1186/1471-2407-11-169
Genes Associated With Prognosis After Surgery For Malignant Pleural Mesothelioma Promote Tumor Cell Survival In Vitro
G. Gordon (2010)
10.1016/J.JTCVS.2019.07.073
Intracavitary cisplatin-fibrin chemotherapy after surgery for malignant pleural mesothelioma: A phase I trial.
I. Opitz (2019)
10.1055/A-0573-2419
Anwendung der hyperthermen intrathorakalen Chemotherapie (HITHOC) in Deutschland
Michael Ried (2018)
10.1007/s00398-010-0802-1
Kombinierte Technik der chirurgischen Zytoreduktion und hyperthermen intrathorakalen Chemotherapieperfusion
M. Ried (2010)
See more
Semantic Scholar Logo Some data provided by SemanticScholar